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AbstrAct
Objective The Fluids in Shock (FiSh) Trial proposes to 
evaluate whether restrictive fluid bolus therapy (10 mL/
kg) is more beneficial than current recommended practice 
(20 mL/kg) in the resuscitation of children with septic shock 
in the UK. This qualitative feasibility study aimed to explore 
acceptability of the FiSh Trial, including research without 
prior consent (RWPC), potential barriers to recruitment and 
participant information for a pilot trial.
Design Qualitative interview study involving parents 
of children who had presented to a UK emergency 
department or been admitted to a paediatric intensive 
care unit with severe infection in the previous 3 years.
Participants Twenty-one parents (seven bereaved) 
were interviewed 16 (median) months since their child’s 
hospital admission (range: 1–41).
results All parents said they would have provided 
consent for the use of their child’s data in the FiSh Trial. 
The majority were unfamiliar with RWPC, yet supported 
its use. Parents were initially concerned about the 
change from currently recommended treatment, yet 
were reassured by explanations of the current evidence 
base, fluid bolus therapy and monitoring procedures. 
Parents made recommendations about the timing of the 
research discussion and content of participant information. 
Bereaved parents stated that recruiters should not discuss 
research immediately after a child’s death, but supported a 
personalised postal ’opt-out’ approach to consent.
conclusions Findings show that parents whose child 
has experienced severe infection supported the proposed 
FiSh Trial, including the use of RWPC. Parents’ views 
informed the development of the pilot trial protocol and 
site staff training.
trial registration number ISRCTN15244462—
results.
IntrODuctIOn
Qualitative research to incorporate patient perspec-
tives in the design of a clinical trial can help ensure 
the trial is acceptable and appropriate to the needs 
of patients and their families.1 This can increase the 
impact of the work, thus benefiting future trials and 
patient-centred healthcare.2 3
Paediatric trials in emergency and critical care 
settings can be challenged by the difficulties of 
seeking prospective informed consent for trial 
participation4 5 as time-critical interventions cannot 
be delayed.6 So that vital research can proceed, clin-
ical trials legislation has been amended7–11 to enable 
children to be entered into a trial without prior 
informed consent.4 12 This is research without prior 
consent (RWPC), also called deferred consent, and 
it entails seeking consent postintervention for the 
use of data already collected and continued study 
participation.10 13 Although RWPC has been subject 
to debate,14–16 recent studies have indicated parental 
support for this approach.1 12 17–20 However, further 
research is needed to explore parent and practi-
tioner views on using RWPC in trials relating to 
more complex situations, such as comparing usual 
clinical care with a change in care, or when a child 
dies after being entered into a trial.1
Rapid fluid replacement by bolus is integral to the 
management of children presenting to UK emergency 
departments (EDs) with septic shock. Current UK 
guidance, recommending fluid boluses of 20 mL/kg,21 
is based on weak evidence.22–24 The Fluid Expansion 
as Supportive Therapy (FEAST) trial25 compared fluid 
bolus resuscitation of 20–40 mL/kg with no bolus 
maintenance fluid in over 3000 African children with 
What this study adds?
 ► Our findings support the proposed Fluids in 
Shock (FiSh) pilot trial and demonstrate the 
value of using qualitative methods to involve 
parents in the design of trials.
 ► Tailored verbal information can help 
address parents’ priorities, concerns and 
misconceptions about FiSh.
 ► This study provides new insight into what 
should happen if a child dies after being 
entered into a trial without prior informed 
consent.
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What is already known on this topic?
 ► Research is needed to determine whether 
restrictive fluid bolus therapy is more 
beneficial than current recommended practice 
in the resuscitation of children with presumed 
septic shock.
 ► Paediatric emergency and critical care trials 
encounter practical and ethical difficulties, as 
there is no time to seek informed consent in an 
emergency situation.
 ► Feasibility work incorporating patient 
perspectives can help test key parameters and 
ensure the trial is appropriate to the needs of 
patients and their families.
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Figure 1 Fluids in Shock qualitative study flow chart. ED, emergency 
department; PICU, paediatric intensive care unit.
severe infection and reported 30% higher mortality with fluid bolus 
resuscitation.25 This raised uncertainty and highlighted the lack of 
evidence for fluid bolus resuscitation for children in middle-income 
and high-income settings.
Accordingly, the Fluids in Shock (FiSh) randomised controlled 
trial (RCT) was designed to determine whether restrictive fluid 
bolus therapy (10 mL/kg) is more beneficial than current UK 
recommended practice (20 mL/kg). Prior to conducting the 
definitive RCT, the need for qualitative feasibility and clinical 
pilot work was identified to explore key challenges, including 
insufficient time to obtain informed consent and delivery of a 
fluid bolus protocol, which deviates from current recommended 
practice. This paper presents findings from the qualitative feasi-
bility study, which aimed to review and explore with parents 
the acceptability of the FiSh Trial, approach to consent, potential 
barriers to recruitment and participant information materials for 
the pilot trial.
MethODs
study design
We conducted semistructured telephone interviews with bereaved 
and non-bereaved parents of children who had presented to 
a UK ED or been admitted to a paediatric intensive care unit 
(PICU) with severe infection in the previous 3 years. Severe 
infection was defined as any condition leading to treatment for 
sepsis or septic shock, for example, meningococcal septicaemia. 
Parents were excluded if they did not speak English. We used 
previous research1 12 26 to develop an interview topic guide 
(see online supplementary file 1 table 1) and draft Participant 
Information Sheet (PIS) for the pilot trial (see online supplemen-
tary file 2). The topic guide contained open-ended questions 
and prompts to help explore parents’ views on the acceptability 
of the FiSh Trial, including the pilot trial PIS and approach 
to consent. A separate section of questions was developed for 
bereaved parents.
recruitment and sampling procedure
Based on previous studies,1 we anticipated recruiting 15–25 
parents. We used three recruitment routes (figure 1).
Recruitment route 1: postal contact
Clinicians used hospital medical records to identify the 15 most 
recent parents (including up to five bereaved) of children who 
met the inclusion criteria. Those identified were sent a postal 
invitation, including a covering letter and qualitative study PIS 
that detailed how to register interest in taking part.
Recruitment route 2: advertising in PICU
A participant information poster and copies of the qualitative 
study PIS were placed in PICU family rooms in hospitals.
Recruitment route 3: advertising online including social media
We posted an advert on Twitter and Facebook and asked relevant 
charities and parent support groups to place the advert on their 
website and social media.
eligibility screening and interview conduct
CBO and KW responded to parents’ requests to participate in 
sequential order, confirmed eligibility and emailed them the 
pilot trial PIS. Audio-recorded verbal consent was sought before 
the interview began.
Digital audio recordings were transcribed verbatim, anony-
mised and checked for accuracy. Respondent validation was used 
to add unanticipated topics to the topic guide as interviewing 
and analysis progressed.27 Interviews aimed for data saturation, 
that is, the point where no new major themes are discovered 
in analysis.28 29 Screening stopped when data saturation28 29 was 
reached. All participants received a £30 shopping voucher and 
letter thanking them for their time.
Analysis
CBO (a psychologist) led the analysis with assistance from 
KW (a sociologist). Analysis was broadly interpretive and iter-
ative30 31 (see online supplementary file 3 table 2). Informed 
by the constant comparative approach, the aim was to provide 
accurate representation of parental views on trial design and 
acceptability.32–35 We used NVivo V.10 software to assist in the 
organisation and coding of data.
results
sample
Four UK hospitals took part in recruitment routes 1 and 2, and 
11 charities/support groups in recruitment route 3. A total of 58 
parents registered interest, of whom 29 were screened (figure 2); 
three were deemed ineligible and five did not confirm a date for 
interview. Data saturation28 29 was reached when 21 parents were 
interviewed (18 mothers (5 bereaved), 3 fathers (2 bereaved)).
Bereaved parents were interviewed on average 11 (median) 
months since admission (range: 3–31) and non-bereaved 
parents on average 16.5 months since admission (range: 1–41). 
The median hospital length of stay for their child was 1 day 
(range: 1–25) for bereaved parents and 14 days (range: 4–140) 
for non-bereaved parents. Eight parents had previously partici-
pated in a clinical trial. One mother had experience of RWPC. 
Interviews took between 30 and 55 min (see online supplemen-
tary file 4 table 3 for selected quotations from parents by theme).
rWPc is acceptable but with some initial concerns
A general definition of RWPC was first read to parents (box 1). 
Many described how they may be initially surprised to discover 
that their child had been entered into a trial without their prior 
consent. However, concerns subsided once reasons for using 
RWPC in emergency situations were considered. Parents went 
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Figure 2 FiSh qualitative study parent recruitment process. For 
families identified using social media, responses were dealt with in the 
order they were received, screened, then interviewed where eligible. 
Data saturation was reached without the need to screen the remaining 
responses. ED, emergency department; FiSh, Fluids in Shock; PICU, 
paediatric intensive care unit. 
box 1 Description of research without prior consent read 
to participants during interview
Due to the need to treat a patient in an emergency without delay, 
or because parents may not always be present when a child 
needs treatment, it is not always appropriate or possible to obtain 
consent before a child is entered into a trial. To enable research to 
be conducted in the emergency setting, many countries (including 
the UK) allow consent to be sought as soon as possible after-
wards. This is for permission to use the data already collected 
and to continue in the trial. This is research without prior consent 
(sometimes called deferred consent). Research without prior 
consent is a relatively new approach to seeking consent in the UK.
box 2 examples of questions raised by parents
 ► Would the amount of fluid given be corrected if my child 
was not stabilising?
 ► Does the amount of fluid have a direct impact on outcome?
 ► What is a fluid bolus?
 ► What is the timing of fluid bolus administrations?
 ► Will I be able to find out which group my child was 
randomised to?
 ► Does the fluid treatment apply regardless of the child’s age?
on to respond favourably to RWPC, describing it as a logical 
solution to enable research in challenging circumstances.
support for Fish trial but with some concerns and 
misconceptions
Overall, parents spoke of their support for FiSh and its use of 
RWPC. Many viewed trial participation as a way to help other 
families and children in the future. Some parents thought that a 
recruitment discussion could provide a “distraction” (P9, mother, 
non-bereaved) and foster “a sense of control in a situation where 
you feel completely out of control” (P6, mother, non-bereaved).
However, support for the FiSh Trial appeared to be dependent 
on the intervention being successful and “how well [their child] 
was” (P4, mother, non-bereaved). Parents, including those who 
were bereaved, said they would question whether their child’s 
participation in the trial was “the reason [their child] didn’t 
survive” (P19, mother, bereaved), in that eventuality.
Some parents held specific concerns and misconceptions, 
which influenced their views on the acceptability of the FiSh 
Trial. Many were concerned that a change from current practice 
may jeopardise their child’s chances of survival. This was linked 
to the misconception that routinely used treatments are proven 
to be effective. Parents were also concerned that restrictive fluid 
bolus therapy would be insufficient as a liberal approach to fluid 
bolus resuscitation was viewed as being more likely to save a 
child’s life.
In response, CBO directed parents to sections of the pilot 
trial PIS and provided tailored explanations, such as the weak 
evidence base for current recommended practice, how fluid 
resuscitation is part of a larger treatment package and moni-
toring procedures. Such tailored explanations appeared to 
address parents’ initial concerns and misconceptions about the 
proposed FiSh Trial.
unclear or missing study information
All parents described the pilot trial PIS as being clear and concise. 
However, parents raised questions about aspects of FiSh (box 2), 
indicating that key information was unclear or missing. Impor-
tantly, this information was prioritised by parents, impacting 
on their understanding and views about the acceptability of the 
trial. Many said they would not ask questions or raise concerns 
with a FiSh recruiter.
When to approach parents to discuss the Fish trial
Parents described how a FiSh Trial discussion should happen 
after the initial stress had subsided and their child’s condition 
had stabilised, preferably within 24–48 hours. Parents expressed 
the need for recruiters to gauge appropriate timing of this discus-
sion in consultation with the clinical team.
We asked bereaved parents to consider a scenario in which 
their child had been entered into FiSh before death and a prac-
titioner approached them after death to discuss the trial. They 
suggested that FiSh recruiters should be prepared to address 
concerns about whether trial participation was “a reason as to 
why [death] happened” (P21, mother, bereaved). They empha-
sised a need for sensitivity and time, particularly if their child 
had died very quickly, without warning. Parents described their 
anger in the initial stages of bereavement, which they believed 
would negatively impact on decision-making abilities and their 
response to a FiSh Trial discussion. Nevertheless, all bereaved 
parents agreed it would be acceptable to discuss FiSh at a later 
time, after they had left hospital. Bereaved parents valued 
medical research and described how they would have consented 
to the use of their child’s data as a way to help other children in 
the future.
We then sought bereaved parents’ views on the most appro-
priate way of contacting parents to discuss FiSh following death 
of a child (box 3). Several parents thought an appropriately 
timed face-to-face discussion with a nurse or consultant would 
be preferable to a telephone call or letter. The majority however 
supported contact via post at 4 weeks and then at 8 weeks after 
death as long as the ‘opt-out’ approach provided was emphasised 
in bold and the letter personalised, ideally by a known member 
of the clinical team. However, parents described grief as a “very 
personal matter” (P17, mother, bereaved), making it difficult 
to develop general recommendations on how best to approach 
parents in this situation.
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box 3 Options for approaching bereaved parents to 
discuss the Fluids in shock trial after a child has died
The researcher presented several options to consider:
 ► Face-to-face discussion with a nurse or doctor
 ► Telephone call by a nurse or doctor
 ► Personalised letter 4 weeks after randomisation, followed 
by a second letter 8 weeks after randomisation (ie, if no 
response is received after sending the initial letter); letters 
would explain how to opt out of the study and that there 
would be no need to respond if they wanted their child’s 
data to be used in the trial
DIscussIOn
This study provides insight into the acceptability of the FiSh 
Trial by exploring the views of parents with relevant experi-
ence. Consistent with the CONNECT  (CONseNt methods 
in paediatric Emergency and urgent Care Trials) study find-
ings1 12 and associated guidance on RWPC,36 37 some parents 
were initially surprised about the concept of RWPC. However, 
initial concerns subsided when reasons why informed consent 
could not be sought were considered. As also shown in 
previous international research,18 38 parents questioned their 
ability to provide a rational, informed decision about research 
in an emergency situation1 4 18 39 and supported alternative 
approaches to prospective informed consent as a way to 
enable research in time-critical situations to improve treat-
ments for critically ill children.1 18 38 40
Our findings highlight specific concerns and misunderstand-
ings, which initially influenced parental views on acceptability 
of the FiSh Trial.19 Concerns included the proposed change from 
current clinical practice and its potential impact on a child's 
recovery. Although the pilot PIS included a description of the 
weak evidence for current practice, many held a misconception 
that this was the proven optimal treatment. Moreover, several 
parents were unclear about the nature of fluid bolus therapy and 
only one understood that 20 mL/kg would be given to all chil-
dren before being entered into FiSh. Nevertheless, all parents 
reported they would have provided consent for the use of their 
child’s data in FiSh, valuing the opportunity to advance medical 
research and viewing their child’s participation as a means 
to help similar families in the future.1 This is consistent with 
previous findings that emphasise the need for simple, non-med-
icalised information to improve parental understanding of trial 
information and inform their research decisions.1 26 41 Tailored 
explanations appeared to address parents’ priorities, concerns 
and misconceptions. These findings were used to develop the 
FiSh pilot trial site staff training, which emphasised the need for 
recruiters to provide opportunities for questions, as parents are 
unlikely to voice potential concerns.19 42
Consistent with previous studies that have explored approaches 
to consent in time-critical situations,1 18 40 43 44 the timing of the 
recruitment discussion was found likely to impact on parental 
responses to FiSh. Although many parents described how consul-
tation with the clinical team would help recruiters gauge when to 
approach families to discuss the trial,37 their views on when and 
how this initial contact should happen differed, depending on 
whether or not their child survived. Parents of children who had 
survived severe infection expressed how they would wish to be 
approached in hospital, ideally within 24–48 hours of randomi-
sation, once their child’s condition had stabilised.36 In contrast, 
bereaved parents emphasised that parents in this situation should 
not be approached immediately after their child’s death, as this 
may heighten feelings of grief and anger. It was this perceived 
burden of having a research discussion with vulnerable families 
that led to a waiver of consent (ie, no trial discussion) when a 
child died in FEAST.18 40 45 However, our findings do not support 
the model used in this study,17 as bereaved parents described how 
they would wish to discuss the use of their child’s information in 
FiSh, as long as the timing of this discussion was appropriate.12 37
Our findings provide new insight into what should happen 
if a child dies after being entered into a trial.36 Although some 
bereaved parents preferred a face-to-face research discussion, the 
majority responded favourably to being contacted via a letter, 
providing the opportunity to meet with a practitioner at a later 
date. Bereaved parents responded favourably to the inclusion of 
their child’s data in the trial unless the family notify the research 
team, provided this ‘opt-out’ approach is emphasised in bold 
text within the letter. Importantly, parents recommended that 
the letter should be sent from a practitioner known to the family 
with whom they had developed a close and trusting rapport.36 
As septic shock is associated with an 8%–17% mortality rate,23 46 
these findings are particularly important and will help design 
a trial that is appropriate to the needs of vulnerable families. 
The views of bereaved parents also highlight the need for practi-
tioners to prepare to respond to parents who are concerned that 
trial participation may have resulted in harm.
strengths, limitations and future implications
While our sample size was relatively small, data saturation was 
reached35 and both bereaved and non-bereaved parents were 
included. As the majority of parents were recruited using social 
media, our sample may comprise parents with an interest in 
research and may not reflect the potential FiSh sample. Although 
all parents had experience of paediatric emergency and critical 
care, the majority had no previous experience of RWPC. Addi-
tional qualitative research will therefore be conducted within the 
FiSh pilot trial to further explore parental acceptability of the 
FiSh Trial, approach to consent and practitioner training needs.
Our findings add to the existing literature on RWPC in 
paediatric emergency and critical care settings. As such, they 
provide an important contribution and demonstrate the value 
of using qualitative methods in considering family-centred 
parameters needed to inform the design and conduct of chal-
lenging trials.47 48
Finally, children were not involved in this study. Research is 
required to explore children’s views on RWPC in emergency and 
critical care trials.
cOnclusIOns
Overall, findings suggest that parents whose child has expe-
rienced severe infection support the proposed FiSh Trial, 
including the use of RWPC. Parents’ views have informed 
the development of the pilot trial protocol and site initiation 
training.
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